← All tickers

Is MRVI Worth Buying in 2026?

Maravai LifeSciences Holdings, Inc. Class A Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-07-26

Here’s whether Maravai LifeSciences Holdings, Inc. Class A Common Stock (MRVI) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+11.59% over 10 days); strong 1-year return of +149.4%; 3-month momentum positive (+90.4%). Currently 9.1% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

MRVI is in a confirmed uptrend, trading above both its 50-day ($5.51) and 200-day ($3.94) moving averages. An RSI of 68.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +149.4% compares to +16.5% for SPY (beat the market by 133.0%).

$10,000 invested 1 year ago → $24,945 today
vs. S&P 500 (SPY) — same period beat market by 133.0%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($3.94)
✓Above 50-day MA ($5.51)
✓RSI(14) neutral zone (30–70) — currently 68.2
✓Positive return (+149.4%)
✓Within 10% of period high (−9.1%)
Period Range $6.76
$1.99 $7.44
RSI (14) 68.2
0 · OversoldOverbought · 100

Key Metrics

Price$6.76
Period Return+149.4%
Period High$7.44
Period Low$1.99
Drawdown−9.1%
MA-50$5.51
MA-200$3.94
RSI (14)68.2
Avg Volume (30d)3.2M
vs. SPYbeat by 133.0%
Return Rank#61 of 999

Trade MRVI

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers